Jubilant Ingrevia Q2 FY27 Revenue Up 24% to ₹1,394 Crore, EBITDA Up 51%
Jubilant Ingrevia reported Q2 FY27 revenue of ₹1,394 crore, up 24% YoY, and EBITDA of ₹221 crore, up 51% YoY. PAT increased 61% to ₹111 crore. The company also announced the acquisition of a 40% stake in ZettaOne Technologies for ₹189.2 crore. An investor conference call is scheduled for October 27, 2026.
The strong financial results, coupled with a strategic acquisition in a new growth area (EDMS), are expected to have a significant positive impact on the company's valuation and future growth trajectory.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with a strategic acquisition, indicating positive financial performance and future growth prospects.
Jubilant Ingrevia Limited announced its financial results for the quarter and half year ended September 30, 2026. The company reported a strong growth momentum in Q2 FY27, with total revenue increasing by 24% year-on-year to ₹1,394 crore and total EBITDA growing by 51% year-on-year to ₹221 crore. Profit After Tax (PAT) after exceptional items rose by 61% year-on-year to ₹111 crore, with diluted EPS at ₹7.1.
The company's performance was driven by strong execution across its businesses, particularly in Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment saw revenue grow by 16% YoY to ₹560 crore, supported by Fine Chemicals and CDMO. The Nutrition segment delivered robust growth with revenue up 50% YoY to ₹270 crore, driven by strong Vitamin B3 volumes. Chemical Intermediates revenue increased by 24% YoY to ₹563 crore, aided by improved realizations.
In a strategic move, Jubilant Ingrevia has signed an agreement to acquire a 40% stake in ZettaOne Technologies Limited for ₹189.2 crore, marking its entry into the Electronics Development and Manufacturing Services (EDMS) space. This acquisition is expected to enhance the company's integrated value proposition in the electronics and semiconductor sectors.
Looking ahead, the company is confident in sustaining its growth momentum, with expected growth across all business segments in FY27. The new Multi-Purpose Plant is on track for commissioning by year-end. The company also announced its participation in an Investors Conference Call scheduled for October 27, 2026, at 5:00 PM IST to discuss these results.
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.